- Home
- SHLS vs IMTX Comparison
SHLS vs IMTX Comparison
Compare SHLS & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHLS | IMTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Germany |
| Employees | N/A | 423 |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SHLS | IMTX |
|---|---|---|
| Price | $6.20 | $9.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 5 |
| Target Price | $9.21 | ★ $19.25 |
| AVG Volume (30 Days) | ★ 5.8M | 469.2K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $475,331,000.00 | N/A |
| Revenue This Year | $25.90 | $1.92 |
| Revenue Next Year | $11.21 | $15.88 |
| P/E Ratio | $30.65 | ★ N/A |
| Revenue Growth | ★ 19.07 | N/A |
| 52 Week Low | $2.92 | $3.30 |
| 52 Week High | $11.36 | $12.41 |
Technical Indicators
Market Signals| Indicator | SHLS | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 49.24 |
| Support Level | $5.49 | $9.61 |
| Resistance Level | $6.26 | $10.83 |
| Average True Range (ATR) | 0.43 | 0.60 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 35.11 | 48.49 |
Price Performance
Historical ComparisonAbout SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.